SCHEMBL6315901

SCHEMBL6315901

NC(=O)c1c(-c2cccs2)noc1NC(=O)c1ccco1

nearest known ligand 0.54

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MAPT P10636 7/20 0.54
ALDH1A1 P00352 7/20 0.54
KMT2A Q03164 5/20 0.54
RAB9A P51151 5/20 0.54
NPC1 O15118 4/20 0.54
SMN1; SMN2 Q16637 4/20 0.54
MEN1 O00255 3/20 0.54
KDM4E B2RXH2 5/20 0.52
HSD17B10 Q99714 5/20 0.52
HPGD P15428 4/20 0.52
POLB P06746 3/20 0.52
GAA P10253 2/20 0.52
TDP1 Q9NUW8 1/20 0.52
TSHR P16473 1/20 0.51
LMNA P02545 3/20 0.50
PPARG P37231 1/20 0.50
NCOA2 Q15596 1/20 0.50
NPSR1 Q6W5P4 1/20 0.50
RXFP1 Q9HBX9 1/20 0.50
NCOR2 Q9Y618 1/20 0.50

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6314886 0.83 MAPT (0.50) MAPTALDH1A1KMT2ARAB9ANPC1
SCHEMBL6316874 0.82 IKBKE (0.57) MAPTALDH1A1KMT2ARAB9ANPC1
SCHEMBL6314638 0.82 ALDH1A1 (0.54) MAPTALDH1A1KMT2ARAB9ANPC1
SCHEMBL6315475 0.82 KIT (0.50) MAPTALDH1A1KMT2ARAB9ANPC1
SCHEMBL6315217 0.79 HTT (0.45) MAPTALDH1A1KMT2ARAB9ANPC1
SCHEMBL6316533 0.79 ADCY1 (0.54) MAPTALDH1A1KMT2ARAB9ANPC1
SCHEMBL6323548 0.79 MAPT (0.52) MAPTALDH1A1KMT2AMEN1KDM4E
SCHEMBL6318710 0.79 HDAC1 (0.43) MAPTALDH1A1KMT2ASMN1; SMN2MEN1
SCHEMBL6318669 0.78 SMN1; SMN2 (0.53) MAPTALDH1A1KMT2ARAB9ANPC1
SCHEMBL6318058 0.78 KMT2A (0.54) MAPTALDH1A1KMT2ARAB9ANPC1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20050059657-A1 Aminoisoxazole derivatives active as kinase inhibitors PFIZER ITALIA S.R.L. (IT) 2005-03-17 US claimed
EP-1435948-A1 AMINOISOXAZOLE DERIVATIVES ACTIVE AS KINASE INHIBITORS Pharmacia Italia S.p.A. (IT) 2004-07-14 EP claimed
WO-2003013517-A1 AMINOISOXAZOLE DERIVATIVES ACTIVE AS KINASE INHIBITORS PHARMACIA ITALIA S.P.A. (IT) 2003-02-20 WO claimed
US-20050059657-A1 Aminoisoxazole derivatives active as kinase inhibitors PFIZER ITALIA S.R.L. (IT) 2005-03-17 US disclosed
EP-1435948-A1 AMINOISOXAZOLE DERIVATIVES ACTIVE AS KINASE INHIBITORS Pharmacia Italia S.p.A. (IT) 2004-07-14 EP disclosed
WO-2003013517-A1 AMINOISOXAZOLE DERIVATIVES ACTIVE AS KINASE INHIBITORS PHARMACIA ITALIA S.P.A. (IT) 2003-02-20 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20050059657-A1 Aminoisoxazole derivatives active as kinase inhibitors MAP3K9, MAP3K19, MAP4K2 MAPT 281/4885ALDH1A1 4444/4885KMT2A 1089/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.